Health knowledge made personal
Posted
Mon 24 May 2010 12:00am
We note that the second Phase III clinical trial of abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic, castration-resistant... interesting studies with abiraterone acetate are now enrolling patients, however:
At the Fred Hutchinson Cancer Center in Seattle, a small, single-arm, Phase II trial is exploring
Read on »
Posted
Mon 04 Oct 2010 12:00am
The “New” Prostate Cancer InfoLink has learned that the results of the Phase III clinical trial of abiraterone acetate + prednisone in patients who progressed after....
As previously reported , we know that the results of this trial are positive. This is confirmed by the title of the actual presentation: “Abiraterone acetate (AA) plus low dose prednisone
Read on »
Posted
Tue 12 Oct 2010 12:00am
for patients who participated in the first Phase III clinical trial of abiraterone acetate, the results of which were announced yesterday ):
Evident, metastatic, castration-resistant... for enrollment in any other ongoing clinical research study of abiraterone acetate
Over 18 years of age
The trial will be designed to monitor side effects of treatment
Read on »
Posted
Thu 18 Feb 2010 12:00am
On Tuesday this week, three papers about abiraterone acetate were published in the on-line version of the Journal of Clinical Oncology. These articles..., and the first stage was met so we will only give the results of the full Phase II study. All patients were treated with 1,000 mg abiraterone acetate, once a day, and the study showed
Read on »
Posted
Mon 11 Oct 2010 12:00am
.
This first Phase III trial of abiraterone acetate , initiated in early 2008, enrolled 1,195 men with mCRPC who had progressive prostate cancer following one or two courses of chemotherapy, including one course of docetaxel-based chemotherapy.
Patients could not have received prior treatment with ketoconazole, abiraterone acetate, any other drug that acts
Read on »
Posted
Wed 14 Jan 2009 8:22pm
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
In this randomised single-blind study..., doug@neurorx.com.
BACKGROUND : Glatiramer acetate (GA) therapy following brief, low-dose induction with mitoxantrone was safe and more effective than GA alone in suppressing inflammatory
Read on »
Posted
Wed 07 Oct 2009 10:01pm
Treatment with glatiramer acetate can reduce by almost half the risk of patients progressing from the very early signs of multiple sclerosis (MS) to clinically definite... to receive either subcutaneous glatiramer acetate 20 mg per day (n = 243) or placebo (n = 238) for up to 36 months, unless they converted to clinically definite MS.
click here
Read on »
Posted
Tue 21 Dec 2010 12:00am
to see abiraterone acetate approved some time in the first 6 months of 2011.
Abiraterone is initially expected to be approved on both sides of the Atlantic for the treatment... have exhausted currently approved treatment options including docetaxel and are likely to benefit from the therapy. For information about early access to abiraterone acetate
Read on »
Posted
Thu 15 Jan 2009 7:22pm
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The REGARD study compared Rebif (interferon beta-1a) 44 mcg and Copaxone (glatiramer acetate) over 96 weeks... interferon-beta and glatiramer acetate. The interferon-beta preparation used in the study was Rebif, and the study was sponsored by EMD Serono and Pfizer, co-marketers of Rebif
Read on »
